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Neurovascular disorders are difficult to
treat due to the blood–brain barrier (BBB),
which prevents delivery of most drugs
from the blood into the brain. Gene ther-
apy can potentially overcome this barrier,
but classical vectors are neither efficient
nor specific enough to provide long-lasting
treatment or avoid off-target effects. In
this issue of EMBO Molecular Medicine,
Körbelin et al (2016) describe an engineered
adeno-associated virus (AAV) with excep-
tional tropism for the brain that restores a
normal phenotype in a mouse model of
incontinentia pigmenti (IP), a severe human
genetic disorder of brain vasculature.
See also: J Körbelin et al
N eurovascular disorders are a hetero-geneous group of pathologies thatdisplay a common characteristic:
they are difficult to treat with traditional
pharmacological approaches. This is largely
due to restraints imposed by the BBB that
limit drug distribution to neurons and glial
cells of the central nervous system (CNS)
upon systemic administration. The BBB is a
highly selective, active interface composed
mainly of vascular endothelial cells, but also
astrocytes and pericytes, as well as neurons,
microglial cells, and smooth muscle cells. In
the brain and spinal cord, endothelial cells
lining the entire inner surface of blood
vessels are linked to one another by tight
junctions, which inhibit transport of most
compounds across the BBB. Astrocyte glial
cells envelop the outer surface of small
blood vessels in the CNS and impose further
restrictions.
In this issue of EMBO Molecular Medi-
cine, et al (2016) apply an innova-
tive in vivo screening system to isolate
engineered AAVs that can deliver transgenes
specifically to the brain in mouse models.
The authors exploited an AAV2 library
displaying random 7-amino acid insertions
on the capsid protein, which was injected
intravenously for reiterated affinity selection
for brain-homing vectors. An AAV display-
ing the NRGTEWD peptide (named AAV-
BR1) was identified that showed high
specificity accompanied by high transgene
expression in the brain with minimal off-
target affinity (including for the liver, for
which the wild-type AAV2 exhibits a strong
tropism). AAV-BR1 revealed substantially
improved transduction efficacy over AAV-
PPS, an AAV2 vector functionalized with
a phage display-selected, brain-specific
peptide (Chen et al, 2009). Stable and
specific transgene expression was detected
in vivo for > 660 days by luciferase-
mediated bioluminescence. This was con-
firmed ex vivo with a relative brain/liver
luciferase activity of 1,000 for AAV-BR1
compared to 10 for AAV-PPS (which was
predominantly detected in the heart).
Although most AAV-BR1, like other
AAVs, was non-specifically entrapped by the
reticuloendothelial system in the spleen, this
organ was not transduced, demonstrating
that ligand-directed AAV delivery is required
for full functionality. In addition, brain
homing was also accompanied by detarget-
ing of other sensitive sites, for example,
liver, heart, and kidneys. The authors identi-
fied brain vessel endothelial cells as the
main target of AAV-BR1, which broadly
transduced CNS-associated capillaries in
various tested brain areas (cerebellum,
olfactory bulb, striatum, cerebral cortex), as
well as in the spinal cord. They also
observed sporadic neuronal transduction,
demonstrating that AAV-BR1—at least to
some extent—can cross the BBB, possibly by
transcytosis through the endothelial layer.
As a proof-of-concept toward medical
applications, the authors used a murine
model of IP (a severe human neurovascular
disease) to evaluate the therapeutic effects
of AAV-BR1 (Fig 1). IP is caused by
heterozygous mutations that inactivate the
Nemo gene (Smahi et al, 2000); patients
exhibit a mild dermal phenotype associated
with major neurological symptoms and
epilepsy due to loss of brain capillaries and
disruption of the BBB (Meuwissen &
Mancini, 2012). Injection of a single intra-
venous dose of the AAV-BR1 vector carrying
a wild-type Nemo gene (AAV-BR1-NEMO)
completely reversed the neurovascular
abnormalities in both heterozygous
(Nemo/+) and brain endothelial cell-condi-
tionally null (NemobeKO) mouse models of
IP. Besides its efficacy at the diseased sites,
two aspects of this ligand-directed gene ther-
apy are noteworthy in terms of clinical
1 University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA. E-mail: rpasqual@salud.unm.edu
2 Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA
3 Department of Oncology, University of Turin, Candiolo, Italy
4 Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
5 Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
6 Division of Hematology and Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA.
E-mail: warap@salud.unm.edu
†These authors contributed equally
DOI 10.15252/emmm.201606407
ª 2016 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 1
Körbelin
Published online: May 10, 2016 
safety: (i) Overexpression of Nemo did not
affect BBB tightness in wild-type animals,
and (ii) AAV-BR1-NEMO did not transduce
peripheral endothelial cells in either normal
or diseased animals. The latter is of particu-
lar relevance because Nemo upregulation in
non-CNS blood vessels can lead to severe
adverse effects such as atherosclerosis
(Gareus et al, 2008).
The data from et al (2016) are a
promising step toward more effective thera-
peutic approaches targeting the CNS, where
synergistic effects can be achieved by a
concomitant intervention on blood vessels
and, potentially, neurons. Both cell types,
indeed, could be transduced in vivo by AAV-
BR1. So far, specific brain transduction has
only been observed with AAVs injected
locally and at high doses (de Backer et al,
2010; Markakis et al, 2010). Although some
natural, for example, AAV2 and AAV9, and
surface-modified serotypes can cross the
BBB (Foust et al, 2009; Yang et al, 2014;
Choudhury et al, 2016), their systemic
administration results in substantial target-
ing of non-CNS tissues such as heart, liver,
and skeletal muscle (Zincarelli et al, 2008).
The only AAV vector described to transduce
brain—but also cardiac—microvascular cells
is the previously mentioned AAV-PPS (Chen
et al, 2009). However, et al (2016)
elegantly demonstrate enhanced functional-
ity of AAV-BR1, identifying it as the first effi-
cient and specific vector for in vivo systemic
administration of a transgene to the brain
endothelium.
Brain endothelial cells not only contri-
bute to the BBB: as a key component of cere-
bral blood vessels, they are functionally
involved in a plethora of neurological
pathologies including stroke, multiple scle-
rosis, epilepsy, and cancer. Depending on
the delivered transgene, transduction of CNS
endothelial cells with the AAV-BR1 vector
could potentially be tuned to improve cere-
bral perfusion after a stroke, impair vascu-
larization of brain tumors, repair or
otherwise modulate the BBB, and directly
target the CNS through systemic blood circu-
lation. However, although genetically stable,
endothelial cells reveal an exceptional
phenotypic plasticity in pathologic condi-
tions, a well-described scenario, for exam-
ple, in cancer. This implies remodeling of
their surface proteome, leading to differen-
tial receptor exposure and/or accessibility.
As a consequence, a targeting ligand
selected in normal conditions, such as the
peptide motif described by et al
(2016), might not be broadly applicable, and
selection of disease-specific addresses will
probably be necessary to achieve similar
results in different contexts. Moreover, for
efficient transgene delivery such a ligand-
targeted AAV must not only recognize its
specific receptor on the cell surface but also
undergo active (receptor-mediated) internal-
ization. Both events may impact on signal
transduction, with different outcomes
depending on the receptor’s function(s).
Interference of gene therapy-induced intra-
cellular pathways with the desired transgene
effect is not expected to be an issue when
targeting a suicide gene to cancer tissues,
but should be carefully evaluated in the case
of therapeutic genes. In this regard, the effi-
cacy of AAV-BR1-NEMO in the IP mouse
model represents an encouraging result in
light of future applications.
In conclusion, et al (2016)
provide a pioneering work to address very
relevant and unmet clinical needs that go
beyond AAV as a gene therapy vector for
the proof-of-concept genetic disorder inves-
tigated. AAV display peptide libraries can
be selected to target any organ of interest,
providing a valuable strategy for
applications in many other diseases not
associated with the neurovascular system.
AAVs are recognized for their low
immunogenicity, ability to transduce non-
dividing cells, long-lasting transgene
expression, non-pathogenicity, and clinical
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Figure 1. Selection and functional validation of brain-targeting AAVs.
Libraries of AAV2 vectors expressing random peptide inserts on their capsid proteins were injected intravenously in mice. The population of AAVs enriched in the brain was
subjected to reiterated selection rounds, leading to the identification of a candidate lead viral vector (AAV-BR1), which was exploited to selectively deliver a therapeutic
transgene (AAV-BR1-NEMO) to mouse models of incontinentia pigmenti, a severe human genetic disorder of brain vasculature.
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safety. Surface-engineered vectors, such as
the one discovered here, add another key
clinically relevant characteristic: unprece-
dented specificity.
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